Literature DB >> 8929863

Chronic intrauterine pulmonary hypertension alters endothelin receptor activity in the ovine fetal lung.

D D Ivy1, J W Ziegler, M F Dubus, J J Fox, J P Kinsella, S H Abman.   

Abstract

Although endothelin (ET) contributes to the regulation of pulmonary vascular tone in the normal fetus, little is known about its role in pulmonary hypertension in the perinatal period. To examine the role of the ETB receptor in the normal ovine fetal lung, we studied the hemodynamic effects of ET-3 (a selective ETB receptor agonist) before and after RES-701 (a selective ETB receptor antagonist). RES-701 (10 mu g/min for 10 min) did not change basal pulmonary tone and blocked pulmonary vasodilation to ET-3 (500 ng/min for 10 min). To examine the effects of experimental perinatal pulmonary hypertension on activity of the ETA and ETB receptors, we studied the hemodynamic effects of ET-3, ET-1 (a nonselective ETA and ETB receptor agonist), and BQ 123 (a selective ETA receptor antagonist) in 12 chronically prepared late gestation fetal lambs after partial ligation of the ductus arteriosus. Serial changes in the pulmonary vascular effects of these agents were measured early (1-3 d) and late (7-10 d) after partial ductus arteriosus ligation. Left lung total pulmonary resistance in the normal late-gestation fetus was 0.62 +/- 0.01 mm Hg/ml/min (n = 4). After partial ductus arteriosus ligation, total pulmonary resistance increased to 1.2 +/- 0.3 (early; p < 0.05 versus normal), and progressively rose to 1.9 +/- 0.2 mm Hg/ml/min (late; p < 0.05 versus early). Intrapulmonary infusion of ET-3 (500 ng/min for 10 min) increased pulmonary blood flow from 94 +/- 11 to 183 +/- 17 mL/min in the normal fetus, but had no effect during late pulmonary hypertension. Infusions of ET-1 (50 ng/min for 30 min) caused transient pulmonary vasodilation followed by vasoconstriction during early pulmonary hypertension. During late pulmonary hypertension, however, infusion of ET-1 caused predominantly vasoconstriction. Pulmonary vasodilation to BQ 123 (100 mu g/min for 10 min) was greater during late than early pulmonary hypertension (43 versus 21%; p < 0.05). After 10 d of ductus arteriosus ligation, immunoreactive ET-1 content in whole lung tissue was 3-fold higher in hypertensive (n = 7) than control (n = 10) lungs (p < 0.05). We conclude that the ETB receptor contributes little to regulation of basal vascular tone in the normal ovine fetal lung and that chronic intrauterine pulmonary hypertension causes the loss of ETB-mediated vasodilation, progressive ETA-mediated vasoconstriction, and increased lung ET-1 content. We speculate that diminished ETB receptor-mediated vasodilation in combination with enhanced ETA receptor-mediated vasoconstriction and increased ET-1 production contributes to high pulmonary vascular resistance in perinatal pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8929863     DOI: 10.1203/00006450-199603000-00010

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  15 in total

1.  Effect of ABT-627 (A-147627), a potent selective ET(A) receptor antagonist, on the cardiopulmonary profile of newborn lambs with surgically-induced diaphragmatic hernia.

Authors:  M Kavanagh; B Battistini; S Jean; J Crochetière; L Fournier; J Wessale; T J Opgenorth; R Cloutier; D Major
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep.

Authors:  Demosthenes G Papamatheakis; Madalitso Chundu; Arlin B Blood; Sean M Wilson
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

3.  Nitric oxide alterations following acute ductal constriction in the fetal lamb: a role for superoxide.

Authors:  Jong-Hau Hsu; Peter Oishi; Dean A Wiseman; Yali Hou; Omar Chikovani; Sanjeev Datar; Eniko Sajti; Michael J Johengen; Cynthia Harmon; Stephen M Black; Jeffrey R Fineman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-02       Impact factor: 5.464

4.  Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension.

Authors:  David Wolf; Nancy Tseng; Gregory Seedorf; Gates Roe; Steven H Abman; Jason Gien
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-13       Impact factor: 5.464

5.  Endothelin-1-Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups.

Authors:  Jason Gien; Nancy Tseng; Gregory Seedorf; Katherine Kuhn; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-10-19       Impact factor: 5.464

6.  Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling.

Authors:  Jason Gien; Gregory J Seedorf; Vivek Balasubramaniam; Neil Markham; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2007-09-06       Impact factor: 21.405

Review 7.  Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.

Authors:  Yuansheng Gao; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

8.  Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep.

Authors:  Jason Gien; Nancy Tseng; Gregory Seedorf; Gates Roe; Steven H Abman
Journal:  Pediatr Res       Date:  2012-11-30       Impact factor: 3.756

9.  Chronic intrauterine pulmonary hypertension increases endothelial cell Rho kinase activity and impairs angiogenesis in vitro.

Authors:  Jason Gien; Gregory J Seedorf; Vivek Balasubramaniam; Nancy Tseng; Neil Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

10.  Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan.

Authors:  C Goissen; L Ghyselen; P Tourneux; G Krim; L Storme; P Bou; Y Maingourd
Journal:  Eur J Pediatr       Date:  2007-08-15       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.